Cantor Fitzgerald analyst Louise Chen said Friday that she does not expect the FDA's warning letter to Pfizer (PFE) to result in any material change in the market for Mylan's (MYL) Epipen in the near term. In a research note titled "No Need To Go Into Shock Yet Over PFE Warning Letter For Epipen," Chen added that she thinks Pfizer will work with the FDA to get the warning letter resolved. This news could be positive for Impax Laboratories (IPXL), which has the capacity to supply 30% of the market, above its current mid-20% range market share, Chen contends. She has a Neutral rating on Mylan and Overweight rating on Impax.